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Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl
proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the
pro-apoptotic proteins noxa and puma. We studied the efficacy of
AT-101 in patients with recurrent chemosensitive extensive-stage
small cell lung cancer (SCLC).
Methods: Patients with recurrent “sensitive” SCLC (defined as no
progression during and no disease recurrence 2 months after
completion of first-line platinum-based chemotherapy) were eligi-
ble. AT-101 was administered 20 mg orally daily for 21 of 28 days
each cycle for up to six cycles. The primary end point was the
objective response rate.
Results: At the time of planned interim evaluation, none of the 14
evaluable patients enrolled in the first stage had any response to
therapy, and the study was closed permanently for further ac-
crual. Three patients (21%) achieved stable disease after two
cycles of therapy. Grade 3 toxicities included anorexia, fatigue,
and nausea/vomiting.
Conclusions: AT-101 is not active in patients with recurrent che-
mosensitive SCLC.
Key Words: Extensive-stage small cell lung cancer, AT-101,
Gossypol.
(J Thorac Oncol. 2011;6: 1757–1760)
Small cell lung cancer (SCLC) accounts for approximately15% of newly diagnosed lung cancer in the United
States.1 Although initial combination chemotherapy is very
effective with response rates of 60 to 80%, the majority of
patients will eventually die of recurrent disease. Although
topotecan has been approved for use in patients with
relapsed SCLC,2 the clinical benefit from salvage therapy
is quite limited. Minimal progress has been made in the
systemic therapy for SCLC over the past 3 decades.3
Clearly, new agents need to be developed to address this
problem.
AT-101 (R-()-gossypol acetic acid) is an orally ad-
ministered Bcl-2 homology (BH3) mimetic which has been
reported to inhibit the heterodimerization of Bcl-xL, Bcl-w,
and Mcl-1 with pro-apoptotic Bcl-2 proteins, thus lowering
the threshold for apoptosis. As the racemic mixture, AT-101
has also been administered to more than 9000 healthy vol-
unteer men as a male contraceptive.4 It has been well toler-
ated with the most common adverse events being gastroin-
testinal toxicities and grade 1/2 fatigue. Other toxicities
include cardiac effects including elevations of troponin levels
and three possibly related cardiac rhythm abnormalities.
Early studies have reported only limited single-agent antitu-
mor activity.5–8
The majority of SCLC tumors overexpress Bcl-2 and
related family members, which can increase resistance to
apoptosis.9 Because AT-101 is a novel small molecule that
inhibits the heterodimerization to the pro-apoptotic Bcl-2
family proteins, the administration of AT-101 could poten-
tially be of value in patients with SCLC. Preclinical activity
of AT-101 in SCLC, alone and in combination with standard
chemotherapy agents, has been demonstrated using in vitro
and in vivo models.10 We, therefore, conducted a phase II
study of single agent AT-101 in patients with chemotherapy-
sensitive relapsed SCLC to characterize its activity.
PATIENTS AND METHODS
Eligible patients had histologically or cytologically
confirmed SCLC with measurable disease per the Response
Evaluation Criteria in Solid Tumors (RECIST)11 and were
previously treated with only one prior platinum-based che-
motherapy regimen. They must have chemotherapy-sensitive
disease defined as no progression during first-line chemother-
apy and no disease recurrence sooner than 2 months after
completion of first-line chemotherapy. Patients had an East-
ern Cooperative Oncology Group performance status of 0 to
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2 and a life expectancy of greater than 12 weeks. Required
laboratory parameters included leukocytes 3,000/L, abso-
lute neutrophil count1,500/L, hemoglobin8 g/dl, plate-
lets 100,000/L, total bilirubin 1.5 mg/dl, aspartate ami-
notransferase (SGOT) and alanine aminotransferase (SGPT)
2.5  institutional upper limit of normal, and serum creat-
inine 1.5 mg/dl (or creatinine clearance 60 ml/min). All
patients must be able to take oral medications on a regular
basis and to give written informed consent. Patients with
treated brain metastases who were clinically stable were
eligible. The protocol was conducted by the Mayo Phase 2
Consortium along with the California Cancer Consortium and
approved by the Institutional Review Boards of all partici-
pating institutions. All patients provided written informed
consent before undergoing treatment.
AT-101 (NSC# 726190) was supplied by the National
Cancer Institute Cancer Therapy Evaluation Program as tab-
lets containing 10 mg of drug. AT-101 was self-administered
at 20 mg orally once per day for 21 consecutive days
followed by a 7-day rest. Treatment was repeated every 4
weeks for up to six cycles or until progressive disease,
unacceptable toxicity, or withdrawal of consent. The dose of
AT-101 was reduced to 10 mg once daily for prestudy-
defined adverse event criteria. Patients who required more
than one dose reduction due to toxicity were removed from
the study.
As a potential biomarker of apoptotic pathway induc-
tion in response to AT-101, peripheral blood mononuclear
cells (PBMC) were collected, where feasible, within 2
weeks before starting AT-101 and on day 2 of therapy.
PBMC were isolated by low-speed centrifugation in CPT
tubes, stored in OCT medium, and frozen at 80°C for
subsequent analysis. Caspase activation in PBMC was
assessed using the Caspase-Glo 3/7 Assay System (Pro-
mega) according to the manufacturer’s instructions. As-
says were performed in triplicate.
The primary end point of this trial was objective re-
sponse rate, determined using RECIST. All patients who
completed at least one postbaseline tumor assessment were
evaluable for response. A two-stage Simon design12 was used
to test the null hypothesis (H0) that the true response prob-
ability is 0.10 versus the alternative hypothesis (H1) that
the true response probability is 0.25. A total of 14 patients
were to be accrued to the first stage. If two or more patients
exhibited disease response, the study was to be continued to
the second stage and an additional 28 patients were to be
enrolled. If 7 or more patients of the 42 patients enrolled
exhibited disease response, the regimen was to be considered
worthy of further study in this population. This design has a
probability (significance level alpha) of 0.10 to reject H0
when H0 is true and a probability of 0.85 to reject H0 when
H1 is true (power). The secondary end points included tox-
icities, time to disease progression, and overall survival as
well as intratumoral Bcl-2 family member expression and
possible induction of the intrinsic apoptotic pathway. All
toxicities were graded according the Common Terminology
Criteria for Adverse Events version 3.0.
RESULTS
From November 2008 to January 2010, 15 patients
were accrued to the study from five sites within the Mayo
Phase 2 Consortium and the California Consortium. Patient
characteristics are summarized in Table 1. The median num-
ber of cycles of AT-101 was 2 (range, 1–6). One patient
discontinued therapy after one cycle of treatment due to
persistent grade 1 thrombocytopenia which failed to recover
to retreatment level of 100,000 per protocol after 3 weeks
and was considered nonevaluable for the primary end point.
Fourteen patients were evaluable for the primary end point at
the interim analysis. Two patients required a dose delay due
to a nonhematologic adverse event. One patient required dose
modification due to a nonhematologic adverse event.
All grade 3/4 toxicities (regardless of attribution) are
summarized in Table 2. Four patients experienced grade 3
adverse events attributable to the study treatment: nausea and
vomiting (one patient), fatigue (one patient), and anorexia
(two patients). Two patients experienced grade 3 hematologic
adverse events (leukopenia), which were determined to be
unrelated to treatment. No grade 4 toxicities were observed.
At the time of planned interim evaluation, among the
14 evaluable patients, no objective responses were observed.
Therefore, accrual to the trial was terminated due to failure to
pass the prespecified interim analysis per study design. Three
patients (21%) achieved stable disease after two cycles but
subsequently progressed on treatment. Median time to pro-
gression was 1.7 months (95% confidence interval: 1.5–2.0
months). Median overall survival was 8.5 months (95%
confidence interval: 8.1–10.2 months) (Figures 1 and 2).
Caspase assays were performed on PBMC samples as a
measure of the extent of activation of the apoptotic signaling
cascade induced by AT-101 in vivo. Only three subjects had
pre- and posttreatment samples available for analysis. There
TABLE 1. Patient Characteristics
Total (N  15)
Age
Mean 64.5
Median 67.0
Range 46.0–76.0
Gender
Male 9 (60%)
Female 6 (40%)
ECOG performance score
0 7 (46.7%)
1 8 (53.3%)
Race
White 13 (86.7%)
Black or African-American 1 (6.7%)
Asian 1 (6.7%)
Ethnicity
Not Hispanic or Latino 15 (100%)
Prior radiation therapy
Yes 12 (80%)
No 3 (20%)
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was marked interpatient variability in caspase activation and
no consistent evidence of apoptotic induction by AT-101
(Figure 3). Only one of the three patients tested demonstrated
evidence of increased caspase activity after AT-101 treat-
ment, with two patients paradoxically showing lower caspase
activity posttreatment. Each of the three patients had progres-
sive disease as their best response.
DISCUSSION
Unfortunately, AT-101 joins the long list of agents that
have shown disappointing results in patients with SCLC. As
a single agent in patients with chemosensitive recurrent
SCLC in this trial, AT-101 did achieve stable disease in three
patients after two cycles of treatment but those patients
progressed while still on therapy. A phase I/II study of
AT-101 in combination with topotecan in recurrent SCLC
was recently published.13 The trial looked at two cohorts:
chemorefractory and chemosensitive. The study did not meet
its primary end points at the planned interim analysis and was
stopped early.
Several hypotheses have been proposed as to the dis-
appointing activity of Bcl-2 inhibitors in SCLC. To date, the
promising preclinical findings with Bcl-2 inhibitors have
failed to materialize in the clinic. A possible explanation is
that the agents do not reach sufficient concentration in the
tumor cells to suppress the Bcl-2 pathway in vivo. Another
contributor to drug resistance could be the long half-life of
Bcl-2 protein. A third explanation is the possibility of off-
target cytotoxic mechanisms and a failure to inhibit apoptotic
induction specifically. In a preclinical study of six Bcl-2
inhibitors, both obatoclax and AT-101 treatment caused cell
death in a caspase-independent manner instead of inducing
classic apoptosis.14 Only ABT-737 was noted to induce
classic apoptosis. This failure to induce caspase-dependent
cell death is in keeping with our limited correlative analyses,
which demonstrated no consistent induction on caspases after
AT-101 treatment. One recent study identified some gene
expression signatures that could predict sensitivity to ABT-
TABLE 2. Grade 3/4 Toxicitiesa
Grade 3
Hematologic
Febrile neutropenia 0 (0%)
Leukopenia 2 (13.3%)
Thrombocytopenia 0 (0%)
Nonhematologic
Anorexia 3 (20.0%)
Bilirubin 1 (6.7%)
Dyspnea 1 (6.7%)
Fatigue 2 (13.3%)
Hyperglycemia 1 (6.7%)
Hypokalemia 1 (6.7%)
Hypomagnesemia 1 (6.7%)
Hyponatremia 4 (26.7%)
Hypophosphatemia 1 (6.7%)
Nausea 2 (13.3%)
Small intestine obstruction 1 (6.7%)
Vomiting 1 (6.7%)
a No grade IV toxicities were observed.
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FIGURE 1. Overall survival (N  15).
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FIGURE 2. Time to progression (N  15).
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FIGURE 3. Relative caspase activity in peripheral blood
mononuclear cells.
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263 in both SCLC and leukemia/lymphoma lines.15 Perhaps,
the combination of the current Bcl-2 inhibitors with agents
that target other areas of the apoptotic pathway may cause
adequate suppression. Another avenue would be to further
explore gene expression signatures as predictors of tumor
sensitivity to target subsets of the patient population that
would be sensitive to Bcl-2 inhibition.
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